Vesalius Biocapital offers venture capital
to young European innovative life science companies
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. We have contributed to developing ten companies since inception, one of which was acquired through a trade sale.
With € 150 million under management in two funds, Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds.
Our companies are based in Europe allowing easy interaction with management.
We invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
The investment strategy is focused on four areas: therapeutics, medical devices, diagnostics and novel food applications.